{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:59:44Z","timestamp":1785268784612,"version":"3.55.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110646","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T14:51:50Z","timestamp":1689346310000},"page":"110646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Biomarkers and biologics related with psoriasis and psoriatic arthritis"],"prefix":"10.1016","volume":"122","author":[{"given":"Weize","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9997","key":"10.1016\/j.intimp.2023.110646_b0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"The Lancet."},{"issue":"9583","key":"10.1016\/j.intimp.2023.110646_b0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"The Lancet."},{"issue":"10281","key":"10.1016\/j.intimp.2023.110646_b0015","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"The Lancet."},{"key":"10.1016\/j.intimp.2023.110646_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: a mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0025","first-page":"1143","article-title":"The global, regional, and national burden of seborrheic dermatitis: results and insights from the Global Burden of Disease 2019 Study","volume":"315","author":"Buja","year":"2023","journal-title":"Arch. Dermatol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/09546630701341949","article-title":"Psoriasis of the face and flexures","volume":"18","author":"van de Kerkhof","year":"2007","journal-title":"J Dermatolog Treat."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10792-014-9950-8","article-title":"Psoriasis beyond the skin surface: a pilot study on the ocular involvement","volume":"35","author":"Campanati","year":"2015","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.intimp.2023.110646_b0040","article-title":"The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front. Med. (Lausanne)."},{"issue":"10136","key":"10.1016\/j.intimp.2023.110646_b0045","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"The Lancet."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0050","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jdv.15539","article-title":"Pruritus Characteristics in a Large Italian Cohort of Psoriatic Patients","volume":"33","author":"Damiani","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110646_b0055","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.autrev.2016.09.004","article-title":"Psoriasis and autoimmunity","volume":"15","author":"Sticherling","year":"2016","journal-title":"Autoimmun Rev."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0060","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7162","key":"10.1016\/j.intimp.2023.110646_b0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature."},{"issue":"9","key":"10.1016\/j.intimp.2023.110646_b0070","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.110646_b0075","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1084\/jem.20160258","article-title":"Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a","volume":"213","author":"Cheung","year":"2016","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.intimp.2023.110646_b0080","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0085","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.5114\/aoms.2016.62923","article-title":"Blockade of IL-23 ameliorates allergic lung inflammation via decreasing the infiltration of Tc17 cells","volume":"12","author":"Cheng","year":"2016","journal-title":"Arch. Med. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0090","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1753425919852156","article-title":"The contribution of IL-17 to the development of autoimmunity in psoriasis","volume":"25","author":"Furue","year":"2019","journal-title":"Innate Immun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol."},{"issue":"33","key":"10.1016\/j.intimp.2023.110646_b0110","doi-asserted-by":"crossref","first-page":"E3422","DOI":"10.1073\/pnas.1400513111","article-title":"IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms","volume":"111","author":"Ha","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: Implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bjd.14546","article-title":"Increased airway inflammation in patients with psoriasis","volume":"175","author":"Damiani","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110646_b0135","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-020-05050-2","article-title":"Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement","volume":"39","author":"Damiani","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","article-title":"Evaluating the economic burden of psoriasis in the United States","volume":"72","author":"Vanderpuye-Orgle","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0145","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1182\/blood.V90.7.2796","article-title":"The Human Antibacterial Cathelicidin, hCAP-18, Is Synthesized in Myelocytes and Metamyelocytes and Localized to Specific Granules in Neutrophils","volume":"90","author":"S\u00f8rensen","year":"1997","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.intimp.2023.110646_b0150","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1073\/pnas.95.16.9541","article-title":"The peptide antibiotic LL-37\/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface","volume":"95","author":"Bals","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"73","key":"10.1016\/j.intimp.2023.110646_b0155","doi-asserted-by":"crossref","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0160","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/annrheumdis-2012-202218","article-title":"The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats","volume":"72","author":"Hoffmann","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/jid.2011.259","article-title":"Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands","volume":"132","author":"Morizane","year":"2012","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.110646_b0175","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"Epub 2014\/12\/04","author":"Lande","year":"201455621","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/eji.201344277","article-title":"Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA","volume":"45","author":"Lande","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.12.009","article-title":"Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17\/TH1 T-cell responses","volume":"127","author":"Hansel","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"31","key":"10.1016\/j.intimp.2023.110646_b0190","doi-asserted-by":"crossref","first-page":"eabb5274","DOI":"10.1126\/sciadv.abb5274","article-title":"Topical nanoparticles interfering with the DNA-LL37 complex to alleviate psoriatic inflammation in mice and monkeys","volume":"6","author":"Liang","year":"2020","journal-title":"Sci Adv."},{"issue":"14","key":"10.1016\/j.intimp.2023.110646_b0195","doi-asserted-by":"crossref","first-page":"12182","DOI":"10.1074\/jbc.M109665200","article-title":"Punctin, a novel ADAMTS-like molecule, ADAMTSL-1, in extracellular matrix","volume":"277","author":"Hirohata","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"46","key":"10.1016\/j.intimp.2023.110646_b0200","doi-asserted-by":"crossref","first-page":"31493","DOI":"10.1074\/jbc.R109.052340","article-title":"A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms","volume":"284","author":"Apte","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2023.110646_b0205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.matbio.2012.09.003","article-title":"A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5) is a novel fibrillin-1-, fibrillin-2-, and heparin-binding member of the ADAMTS superfamily containing a netrin-like module","volume":"31","author":"Bader","year":"2012","journal-title":"Matrix Biol."},{"issue":"13","key":"10.1016\/j.intimp.2023.110646_b0210","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.110646_b0215","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/exd.13378","article-title":"Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes","volume":"26","author":"Fuentes-Duculan","year":"2017","journal-title":"Exp. Dermatol."},{"issue":"13","key":"10.1016\/j.intimp.2023.110646_b0220","doi-asserted-by":"crossref","first-page":"12890","DOI":"10.1074\/jbc.M305801200","article-title":"Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2delta, induced in psoriatic skin","volume":"279","author":"Chiba","year":"2004","journal-title":"J Biol Chem."},{"key":"10.1016\/j.intimp.2023.110646_b0225","article-title":"Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema","volume":"6(244):244ra90","author":"Quaranta","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"20","key":"10.1016\/j.intimp.2023.110646_b0230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151911","article-title":"Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris","volume":"6","author":"Shao","year":"2021","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101773","article-title":"Moesin and stress-induced phosphoprotein-1 are possible sero-diagnostic markers of psoriasis","volume":"9","author":"Maejima","year":"2014","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0240","first-page":"407","article-title":"Isolation of virus-like particles in urine from a psoriatic patient","volume":"91","author":"Iversen","year":"1983","journal-title":"Acta Pathol. Microbiol. Immunol. Scand. B."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0245","first-page":"343","article-title":"Urine proteins cross-reacting with antiserum against virus-like particles from cultured psoriatic epithelial cells","volume":"91","author":"Iversen","year":"1983","journal-title":"Acta Pathol. Microbiol. Immunol. Scand. B."},{"issue":"174","key":"10.1016\/j.intimp.2023.110646_b0250","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.11.006","article-title":"Pso p27, a SERPINB3\/B4-derived protein, is most likely a common autoantigen in chronic inflammatory diseases","volume":"Epub 2016\/11\/23","author":"Iversen","year":"2017","journal-title":"Clin Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0255","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann. Rheumatic Diseases."},{"key":"10.1016\/j.intimp.2023.110646_b0260","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cca.2020.07.037","article-title":"Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab","volume":"510","author":"Patrikiou","year":"2020","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.intimp.2023.110646_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.893086","article-title":"Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status","volume":"13","author":"Matsuda","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110646_b0270","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis","volume":"135","author":"Nast","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0275","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/1346-8138.14578","article-title":"Increase in antinuclear antibody levels through biologic treatment for psoriasis","volume":"46","author":"Miki","year":"2019","journal-title":"J. Dermatol."},{"issue":"2\u20133","key":"10.1016\/j.intimp.2023.110646_b0280","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12026-013-8410-2","article-title":"Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab","volume":"56","author":"Lora","year":"2013","journal-title":"Immunol Res."},{"issue":"11","key":"10.1016\/j.intimp.2023.110646_b0285","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/1346-8138.16102","article-title":"Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients","volume":"48","author":"Sugiura","year":"2021","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0290","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1365-2133.2012.11149.x","article-title":"Concepts in psoriasis: psoriasis and the extracellular matrix","volume":"167","author":"McFadden","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0295","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/1346-8138.13667","article-title":"Increased circulating anti-alpha6-integrin autoantibodies in psoriasis and psoriatic arthritis but not in rheumatoid arthritis","volume":"44","author":"Gal","year":"2017","journal-title":"J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0300","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800114","article-title":"Discovery of IgG4 Anti-Gliadin Autoantibody as a Potential Biomarker of Psoriasis Using an Autoantigen Array","volume":"14","author":"Qiu","year":"2020","journal-title":"Proteomics Clin. Appl."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0305","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/eji.201445293","article-title":"Heat shock protein 90 associates with Toll-like receptors 7\/9 and mediates self-nucleic acid recognition in SLE","volume":"45","author":"Saito","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12192-016-0670-z","article-title":"Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies","volume":"21","author":"Tukaj","year":"2016","journal-title":"Cell Stress Chaperones."},{"key":"10.1016\/j.intimp.2023.110646_b0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/molecules23112846","article-title":"Heat Shock Proteins as Immunomodulants","volume":"23","author":"Zininga","year":"2018","journal-title":"Molecules."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00005-020-00573-7","article-title":"Antibodies to Heat Shock Proteins 90alpha and 90beta in Psoriasis","volume":"68","author":"Damasiewicz-Bodzek","year":"2020","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)."},{"issue":"10","key":"10.1016\/j.intimp.2023.110646_b0325","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/rheumatology\/kew229","article-title":"Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis","volume":"55","author":"Behrens","year":"2016","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14397595.2019.1586085","article-title":"Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis","volume":"30","author":"Hagiwara","year":"2020","journal-title":"Mod. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0335","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/art.40830","article-title":"Identification of Novel Autoantibodies Associated With Psoriatic Arthritis","volume":"71","author":"Yuan","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2023.110646_b0340","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0345","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/cei.13376","article-title":"Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis","volume":"199","author":"De Andrea","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110646_b0350","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.autrev.2015.08.003","article-title":"Auto-reactions, autoimmunity and psoriatic arthritis","volume":"14","author":"Chimenti","year":"2015","journal-title":"Autoimmun Rev."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The Role of Tumor Necrosis Factor Alpha (TNF-alpha) in Autoimmune Disease and Current TNF-alpha Inhibitors in Therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2\u20133","key":"10.1016\/j.intimp.2023.110646_b0360","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases","volume":"38","author":"Emi Aikawa","year":"2010","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2023.110646_b0365","doi-asserted-by":"crossref","unstructured":"Feldman SR, Reznichenko N, Pulka G, Kingo K, George G, Berti F, et al. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study. BioDrugs. 2021;35(6):735-48. Epub 2021\/10\/18. doi: 10.1007\/s40259-021-00502-w. PubMed PMID: 34657274; PubMed Central PMCID: PMCPMC8520467 research grants from Abbvie, Janssen, Lilly and Novartis and speaker honoraria from Alvotech, Abbvie, Amgen, Lilly, Novartis and Janssen. RK's company has received consultancy fees in relation to this study and in other studies conducted by Alvotech, but no consultancy fees have been received in relation to the writing of this manuscript. NR, GP, KK, and GG declare that they have no conflicts of interest that might be relevant to this work.","DOI":"10.1007\/s40259-021-00502-w"},{"key":"10.1016\/j.intimp.2023.110646_b0370","unstructured":"Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, et al. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022;23(5):719-28. Epub 2022\/08\/08. doi: 10.1007\/s40257-022-00708-w. PubMed PMID: 35934770; PubMed Central PMCID: PMCPMC9464749 Pharma, and UCB; he reported consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Biocon, Janssen Biotech, LEO Pharma, Novartis, Sun Pharma, and UCB; honoraria for lectures\/presentations\/speaker bureaus from AbbVie, Amgen, Eli Lilly, Janssen, Sun Pharma, and UCB; travel support from Boehringer Ingelheim, Eli Lilly, and Sun Pharma; and participated in data safety monitoring\/advisory boards for Amgen and Boehringer Ingelheim. Stanley Cohen received grant support from AbbVie, Amgen, BMS, Genentech, Lilly, Pfizer, and Roche; he reported consulting fees from AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Genentech, and Pfizer; honoraria from Novartis and Pfizer; and participated in a data safety monitoring board for Gilead Sciences. Jonathan Kay received grant support from Aker BioMarine, Alliance for Lupus Research, AMPEL BioSolutions, Gilead Sciences, Novartis, Pfizer, and UCB; he reported royalty fees from UpToDate; consulting fees from AbbVie, Alvotech, Boehringer Ingelheim, Celltrion Healthcare, Horizon Therapeutics, Jubilant Radiopharma, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Samsung Bioepis, Sandoz, Scipher Medicine, and UCB; and participated in data safety\/advisory boards for Bristol Myers Squibb, Inmagene, and Kolon TissueGene. Vibeke Strand reported consulting fees from AbbVie, Amgen, Arena, Aria, AstraZeneca, Bayer, Bioventus, BMS, Boehringer Ingelheim, Celltrion, Chemocentryx, EMD Serono, Flexion, Galapagos, Genentech\/Roche, Gilead, GSK, Horizon, Ichnos, Inmedix, Janssen, Kiniksa, Eli Lilly, Merck, MiMedx, Novartis, Pfizer, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Servier, Setpoint, Sun Pharma, Tonix, and UCB. Alice Gottlieb received honoraria as an advisory board member and consultant for AnaptsysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb Co., GSK, Janssen, Eli Lilly, Leo, Novartis, Pfizer, Sun Pharmaceuticals, UCB, Dermavant, and Xbiotech; and received research\/educational grants from Boehringer Ingelheim, Janssen, Novartis, UCB, and Sun Pharmaceutical Industries, Inc. Stephen Hanauer received grant support from AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, and UCB; he reported consultancy fees from AbbVie, Allergan, Amgen, Arena, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cosmos, Catalys Pacific, Covance, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, Takeda, TLL Pharma, UCB, and VHSquared; speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and participated in data safety monitoring boards for Arena, Boehringer Ingelheim; Bristol Myers Squibb, Gossamer, Prometheus, and Protagonist. Susanne Buschke, Karl-Heinz Liesenfeld, Jennifer Schaible, Dorothy McCabe, and Benjamin Lang reported being employees of Boehringer Ingelheim. Sravan Kumar Eduru was previously employed by Boehringer Ingelheim."},{"key":"10.1016\/j.intimp.2023.110646_b0375","doi-asserted-by":"crossref","unstructured":"Yu C, Zhang F, Ding Y, Li Y, Zhao Y, Gu J, et al. A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis. Int Immunopharmacol. 2022;112:109248. Epub 2022\/09\/21. doi: 10.1016\/j.intimp.2022.109248. PubMed PMID: 36126411.","DOI":"10.1016\/j.intimp.2022.109248"},{"issue":"12","key":"10.1016\/j.intimp.2023.110646_b0380","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/jdv.17486","article-title":"Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial","volume":"35","author":"Warren","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0385","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.19393","article-title":"Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)","volume":"184","author":"Gordon","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0390","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjd.19314","article-title":"Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2019.07.103","article-title":"Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis","volume":"82","author":"Wu","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"17","key":"10.1016\/j.intimp.2023.110646_b0400","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA."},{"issue":"23","key":"10.1016\/j.intimp.2023.110646_b0405","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0415","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatol. Ther. (Heidelb)."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0425","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaad.2022.04.060","article-title":"Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial","volume":"88","author":"Kim","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0430","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0435","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"10235","key":"10.1016\/j.intimp.2023.110646_b0440","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0445","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/rheumatology\/keac358","article-title":"Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries","volume":"62","author":"Glintborg","year":"2023","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0450","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J. Am. Acad Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0455","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2021.06.878","article-title":"Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0460","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjd.21701","article-title":"Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis","volume":"187","author":"Ito","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110646_b0465","unstructured":"A.S. Paller, M.M.B. Seyger, G.A. Magarinos, A. Pinter, J.C. Cather, C. Rodriguez-Capriles, et al. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. JAMA Dermatol. 2022;158(5):533-41. Epub 2022\/04\/14. doi: 10.1001\/jamadermatol.2022.0655. PubMed PMID: 35416908; PubMed Central PMCID: PMCPMC9008559 consulting from Eli Lilly, AbbVie, UCB, LEO Pharma, and Exicure outside the submitted work as well as receiving grants to institution as an investigator from Eli Lilly, AbbVie, Janssen, Novartis, and UCB outside the submitted work. Dr Seyger reported receiving grants from Eli Lilly and other funding from Amgen, Janssen, and Novartis outside the submitted work. Dr Magarinos reported receiving personal fees from AbbVie, Biogen, Boehringer, Eli Lilly and Co, Janssen, Novartis, and Pfizer outside the submitted work. Dr Cather reported receiving personal fees for advisory board, speaking, and\/or clinical trial from AbbVie, Amgen, Bristol Myers Squibb, Celgene, ChemoCentryx, Galderma, UCB, Janssen, Anaptys, and Eli Lilly outside the submitted work. Dr Somani reported receiving other as an employee and minor shareholder from Eli Lilly during the conduct of the study. Dr Garrelts reported receiving other as an employee and shareholder from Eli Lilly during the conduct of the study and outside the submitted work. Dr Papp reported receiving grants, personal fees, and other as a consultant from Eli Lilly during the conduct of the study as well as receiving grants and other as a consultant from AbbVie, UCB, and Novartis; other as a consultant from Sandoz; grants from Amgen, Arcutis, Avillion, Bausch Health, Dermavant, Incyte, LEO Pharma, Pfizer, and Sun Pharma; and personal fees from Bausch Health, Bristol Myers Squibb, Dermavant, and Novartis outside the submitted work. No other disclosures were reported."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0470","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0475","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaad.2020.11.013","article-title":"Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors","volume":"84","author":"Yeung","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0480","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2022.1863","article-title":"Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series","volume":"158","author":"Enevold","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"10273","key":"10.1016\/j.intimp.2023.110646_b0485","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.intimp.2023.110646_b0490","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.42280","article-title":"Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study","volume":"74","author":"Coates","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"10370","key":"10.1016\/j.intimp.2023.110646_b0495","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0500","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/bjd\/ljac021","article-title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial","volume":"188","author":"Thaci","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"10370","key":"10.1016\/j.intimp.2023.110646_b0505","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet."},{"issue":"10273","key":"10.1016\/j.intimp.2023.110646_b0510","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0515","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0520","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110646_b0525","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"issue":"10230","key":"10.1016\/j.intimp.2023.110646_b0530","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"The Lancet."},{"issue":"10230","key":"10.1016\/j.intimp.2023.110646_b0535","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"The Lancet."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0540","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials","volume":"82","author":"Reich","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0545","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0550","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0555","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.110646_b0560","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0565","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jdv.18572","article-title":"Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT","volume":"37","author":"Tsianakas","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0570","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0575","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjd.20481","article-title":"Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naive patients with moderate-to-severe plaque psoriasis: a randomized controlled trial","volume":"186","author":"Thaci","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0580","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0585","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Ostor","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0590","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/rheumatology\/keac342","article-title":"Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology (Oxford)."},{"issue":"11","key":"10.1016\/j.intimp.2023.110646_b0595","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","article-title":"Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results","volume":"80","author":"Smolen","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0600","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","article-title":"Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study","volume":"81","author":"Gossec","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.110646_b0605","doi-asserted-by":"crossref","unstructured":"F. Poizeau, E. Nowak, S. Kerbrat, B. Le Nautout, C. Droitcourt, M.D. Drici, et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12\/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020;156(11):1208-15. Epub 2020\/09\/10. doi: 10.1001\/jamadermatol.2020.2977. PubMed PMID: 32902568; PubMed Central PMCID: PMCPMC7489429 National Agency for Medicines and Health Products Safety (ANSM) during the conduct of the study. Dr Bachelez reported receiving personal fees from AbbVie, Almirall, Amgen, Baxalta, Celgene, Dermavant, Eli-Lilly, Janssen, Kyowa Kirin, Novartis, Mylan, Sun Pharmaceuticals, and UCB; and grants and personal fees from Boehringer Ingelheim, Leo Pharma, and Pfizer outside the submitted work. Dr Ait-Oufella reported receiving personal fees from Pfizer, AbbVie, UCB Pharma, and Lilly during the conduct of the study. Dr Oger reported receiving grants from ANSM during the conduct of the study and outside the submitted work. Dr Dupuy reported receiving grants and nonfinancial support from ANSM (French National Agency for Medicines and Health Products Safety) during the conduct of the study. No other disclosures were reported.","DOI":"10.1001\/jamadermatol.2020.2977"},{"issue":"8","key":"10.1016\/j.intimp.2023.110646_b0610","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1111\/jdv.18110","article-title":"Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488)","volume":"36","author":"Mah\u00e9","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereology : JEADV."},{"issue":"11","key":"10.1016\/j.intimp.2023.110646_b0615","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543770903313753","article-title":"PDE4 inhibitors: a review of current developments (2005\u20132009)","volume":"19","author":"Pag\u00e8s","year":"2009","journal-title":"Expert Opin Ther Pat."},{"issue":"12","key":"10.1016\/j.intimp.2023.110646_b0620","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol."},{"issue":"23","key":"10.1016\/j.intimp.2023.110646_b0625","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312878","article-title":"Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1beta Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation","volume":"22","author":"Meier-Schiesser","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J. Am. Acad. Dermatol.."},{"issue":"4","key":"10.1016\/j.intimp.2023.110646_b0635","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.20083","article-title":"Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study","volume":"185","author":"Van Voorhees","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0640","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110646_b0645","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021276","article-title":"Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment","volume":"24","author":"Wolk","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2023.110646_b0650","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/joim.13447","article-title":"The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast","volume":"291","author":"Arias de la Rosa","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.intimp.2023.110646_b0655","unstructured":"Hoy SM. Deucravacitinib: First Approval. Drugs. 2022;82(17):1671-9. Epub 2022\/11\/20. doi: 10.1007\/s40265-022-01796-y. PubMed PMID: 36401743; PubMed Central PMCID: PMCPMC9676857 offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0660","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0665","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0670","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110646_b0675","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110646_b0680","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/09546634.2020.1840502","article-title":"Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data","volume":"33","author":"Damiani","year":"2022","journal-title":"J. Dermatolog. Treat."},{"issue":"12","key":"10.1016\/j.intimp.2023.110646_b0685","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.36849\/JDD.2020.5006","article-title":"Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)","volume":"19","author":"Damiani","year":"2020","journal-title":"J. Drugs Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110646_b0690","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/bjd.13988","article-title":"Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma","volume":"173","author":"Malerba","year":"2015","journal-title":"Br. J. Dermatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:27:19Z","timestamp":1736432839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923009712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":138,"alternative-id":["S1567576923009712"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110646","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers and biologics related with psoriasis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110646"}}